Tricuspid atresia
ORPHA:1209Morphological anomalyNot applicableAntenatal, Neonatal
Фенотипы (HPO)10
Облигатный (100%)1
HP:0011662Tricuspid atresia
Очень частый (80–99%)2
HP:0000961Cyanosis
HP:0001629Ventricular septal defect
Частый (30–79%)5
HP:0001631Atrial septal defect
HP:0001655Patent foramen ovale
HP:0001669Transposition of the great arteries
HP:0004762Hypoplasia of right ventricle
HP:0005301Persistent left superior vena cava
Периодический (5–29%)2
HP:0001680Coarctation of aorta
HP:0004935Pulmonary artery atresia
Эпидемиология19
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Prevalence at birth | 1-9 / 100 000 | 5.5625 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Europe | Class only |
| Prevalence at birth | 1-9 / 100 000 | 5.9 | Belgium | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 9 | France | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 3 | Germany | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 10.5 | Ireland | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 6.5 | Italy | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 4 | Netherlands | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 3.3 | Norway | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 1.5 | Poland | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 1.9 | Spain | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 11.1 | Portugal | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 12.6 | Switzerland | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 5 | United Kingdom | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 9.7 | Ukraine | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 4.6 | Taiwan, Province of China | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 8 | Malta | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 6 | Czech Republic | Value and class |
| Prevalence at birth | 1-9 / 100 000 | 3 | Slovakia | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)